Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-10-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.) injections of irradiated autologous tumor cells that had been established as short-term cell lines, in conjunction with their own dendritic cells (DC) and granulocyte macrophage colony-stimulating factor \[GM-CSF\]. Eligible patients had regionally recurrent and/or distant metastatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

NCT00436930

Melanoma (Skin)

COMPLETED PHASE2

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

NCT00012064

Melanoma (Skin)

COMPLETED PHASE1/PHASE2

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

NCT03300843

Melanoma Gastrointestinal Cancer Breast Cancer +2 more

TERMINATED PHASE2

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

NCT00107159

Melanoma (Skin)

COMPLETED PHASE2

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

NCT02122861

Melanoma - Currently Enrolling Non-small Cell Lung Cancer - Enrollment Completed Sarcoma - Enrollment Completed

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients were stratified by whether they had no measurable disease \[NMD\] at the time of treatment (usually because of surgical resection of metastases), or whether they had objectively measurable disease (OMD) by physical examination or radiologic scans per response evaluation criteria in solid tumors (RECIST criteria). Key endpoints were the results of delayed type hypersensitivity (DTH) skin testing to their own irradiated tumor cells, event-free survival \[death or disease progression\], overall survival, and objective tumor regression in patients who have measurable disease at the time vaccine therapy was initiated. This study was activated in the fall of 2000, and closed to accrual in June 2007.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous tumor cells plus dendritic cells

A series of 8 vaccinations are administered over 6 months

Intervention Type BIOLOGICAL

GM-CSF

500 mcg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sargramostim

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recurrent or metastatic melanoma as defined by stage IV disease (distant metastases), or any recurrent melanoma manifested by lymph node metastases or soft tissue nodules
* ECOG Performance status of 0-2
* Satisfactory medical condition for treatment in a phase I-II trial of anticancer therapy
* Age \> 16 years
* Venous access for leukopheresis procedure to obtain peripheral blood lymphocytes to generate dendritic cells.
* Serum pregnancy test must be negative for women of childbearing potential.

Exclusion Criteria

* Active central nervous system metastases
* Known autoimmune disease or disease process that involves the use of immunosuppressive therapy.
* Underlying cardiac disease associated with New York Heart Association class III or IV function, or unstable angina related to atherosclerotic cardiovascular disease.
* Ongoing transfusion requirements, no significant hepatic or renal dysfunction, creatinine \< 2.0 mg/dl, bilirubin \< 2.0 mg/dl, albumin \> 3.0 mg/dl, hematocrit \> 25, platelets \> 100,000.
* Active infection or other active medical condition that could be eminently life threatening, including no active blood clotting or bleeding diathesis.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No